US 12,006,358 B2
Antibody against advanced glycation end products and use thereof
Tetsuro Yamamoto, Kumamoto (JP); Shota Tsuchida, Kumamoto (JP); Tomoaki Shigeta, Kumamoto (JP); Kazumi Sasamoto, Kumamoto (JP); and Mami Chirifu, Kumamoto (JP)
Assigned to BLOOM TECHNOLOGY CORPORATION, Kumamoto (JP)
Appl. No. 17/271,381
Filed by Bloom Technology Corporation, Kumamoto (JP)
PCT Filed Aug. 30, 2019, PCT No. PCT/JP2019/034195
§ 371(c)(1), (2) Date Feb. 25, 2021,
PCT Pub. No. WO2020/045646, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 2018-163668 (JP), filed on Aug. 31, 2018; and application No. 2018-248166 (JP), filed on Dec. 28, 2018.
Prior Publication US 2021/0221879 A1, Jul. 22, 2021
Int. Cl. C07K 16/18 (2006.01); C07D 241/12 (2006.01)
CPC C07K 16/18 (2013.01) [C07D 241/12 (2013.01); C07K 2317/92 (2013.01)] 2 Claims
OG exemplary drawing
 
1. A compound represented by formula (I) or (II):

OG Complex Work Unit Chemistry
wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, a protecting group, and a peptide group having 1 to 1000 amino acid residues,
X1 and X2 represent —O— or —NH—;
Y1 and Y2 are a hydrogen atom, a protecting group, or a group:

OG Complex Work Unit Chemistry
R5 and R6 are each independently selected from a hydrogen atom, a protecting group, and a peptide group having 1 to 1000 amino acid residues;
or a cationic radical thereof, or a dication thereof or a salt thereof.